There are currently 61 active Crohn’s disease clinical studies underway in the world today, and another 204 more studies that are currently seeking to recruit CD patients, the majority of which are seeking to test novel treatments for the disease. Yet, in spite of all of this research and development into Crohn’s disease therapies, a recent market analysis indicates that the global Crohn’s disease market value is forecast to show modest growth over the next eight years.
The report, which was published by GlobalData, forecasts that the CD market will climb from $3.2 billion in 2012 to $4.2 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.8% — a gain that has been characterized as modest.
According to the company’s latest report, out of the 10 major markets in the world — the U.S., France, Germany, Italy, Spain, the UK, Japan, Canada, China and India — the United States will continue to hold the largest CD market share by 2022 at 68%, followed by Canada and Japan with 8% and 7%, respectively.
The report does boast some future hopes, however, on new drug technologies that are beginning to emerge in the Crohn’s disease market, namely, “the anticipated launch of the first non-anti-tumor necrosis factor (TNF) biologics, such as Takeda’s Entyvio (vedolizumab) and Johnson & Johnson’s (J&J’s) Stelara (ustekinumab).” Of these, Tina Healy, GlobalData’s Director for Immunology, believes that Johnson & Johnson is best positioned to remain a key contender over the forecast period, thanks to Stelara (ustekinumab). While the company will realize losses from a major patent expiry for its leading brand Remicade (infliximab), Stelara, which is expected to launch in 2015, will mitigate those losses.